Zhiyu Pang

Dr. Zhiyu Pang

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Dermatologic Therapy
Verified
Journal Article
Open access
ZPZhiyu Pang
Zhiyu Pang
SZShan Zhang
Shan Zhang
ZLZhaorui Liu
Zhaorui Liu
WZWei Zhang
Wei Zhang
Jie LiuJie Liu
Jie Liu
Brentuximab vedotin (BV) has been approved for CD30‐positive cutaneous T‐cell lymphoma (CTCL) after at least one previous systemic treatment in China. However, real clinical practice is still limited. We aim to retrospectively review our experience with BV in a cohort of Chinese patients with CTCL, focusing on its efficacy and safety. We included 17 CTCL patients treated with BV at Peking Union Medical College Hospital from January 2021 to June 2024, including 12 with mycosis fungoides (MF)/Sézary syndrome (SS) and five with primary cutaneous anaplastic large‐cell lymphoma (pc‐ALCL). Patients had previously received a median of three treatment regimens (including acitretin, interferon, methotrexate, histone deacetylase inhibitors, phototherapy, radiotherapy, and chemotherapy). Sixteen patients received BV treatment at an initial dose of 1.8 mg/kg intravenously every 3 weeks, either as monotherapy (7/17) or in combination with gemcitabine, chidamide, or multiagent chemotherapy. The median treatment cycle has six cycles. Two patients received BV as the last treatment before undergoing allogeneic stem cell transplantation (alloSCT). The overall response rate (ORR) was 71% (13/17), with 18% (3/17) achieving complete remission (CR). In the MF/SS group, the ORR was 58% (7/12), while in the pc‐ALCL group, it was 100% (5/5). Adverse events (AEs) were observed in 12 patients, including peripheral neuropathy (PN) in three cases, fever in six cases, neutropenia in three cases, exfoliative dermatitis in two cases, and abnormal liver function in one case. Only one patient experienced ≥ Grade 3 AEs. Based on clinical experience in our center, BV, either as monotherapy or combined with chemotherapy, showed a good response in the treatment of advanced CTCL patients with good tolerability.

17 April 2026 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
SZShan Zhang
Shan Zhang
ZPZhiyu Pang
Zhiyu Pang
JLJie Liu
Jie Liu

6 November 2026 in Medicina
Verified
Journal Article
Open access
PDF file
Xingyu LiXingyu Li
Xingyu Li
SZShan Zhang
Shan Zhang
ZPZhiyu Pang
Zhiyu Pang
DMDong-Lai Ma
Dong-Lai Ma
Jie LiuJie Liu
Jie Liu
Background and Objectives: Folliculotropic mycosis fungoides (FMF) is a rare variant of mycosis fungoides with diverse clinical manifestations and heterogeneous outcomes. An FMF-specific clinicopathologic staging system has been proposed; however, its utility remains insufficiently validated, particularly in Asian populations. This study aimed to characterize clinicopathologic features of FMF and explore associations between this staging system and survival outcomes in a Chinese cohort. Materials and Methods: This retrospective study included patients diagnosed with FMF at a tertiary center from 1 January 2013 to 1 January 2026. After blinded histopathologic review by two dermatopathologists, patients were classified as early skin-limited (ES), advanced skin-limited (AS), or extracutaneous (EC) according to the FMF-specific staging system. Progression-free survival (PFS) was the primary endpoint; overall survival (OS) was secondary. Analyses used Kaplan–Meier estimation, log-rank tests, and univariable Cox regression. An exploratory plaque-stage subgroup analysis was performed. Results: Among 32 patients, 22 (68.8%) were male; median age at diagnosis was 48.5 years. Furthermore, 9 patients had ES, 20 AS, and 3 EC disease. Moreover, 18 (56.3%) patients had prior misdiagnoses, and 27 (84.4%) had head and/or neck involvement. During a median follow-up of 29 months, 20 PFS events and 3 deaths occurred. PFS differed significantly among clinicopathologic stages (p = 0.004). Median PFS was not reached in ES, compared with 15 months in AS and 9 months in EC stage. Older age, advanced FMF-specific stage, advanced TNMB stage, and angioinvasion/angiodestruction were associated with shorter PFS in univariable analyses. OS did not differ significantly across stages (p = 0.430). Among 15 plaque-stage patients (6 ES, 9 AS), AS had a higher estimated hazard of progression, without statistical significance (HR, 2.91; 95%CI, 0.55–15.28; p = 0.206). Conclusions: FMF-specific clinicopathologic staging was associated with PFS in this Chinese cohort. These exploratory findings support further evaluation of histopathologic stratification, particularly in plaque-stage disease.